Clinical Trial

Curcumin and Retinal Study

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-15; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2023-08-21
Trial Details
NCT Number NCT05774704
Lead Sponsor Texas Tech University Health Sciences Center
Conditions Bioavailability, Gut Microbiome, Safety
Enrollment 60 participants
Start Date 2023-08-21
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-13